Dayvigo
Product Images NDC 62856-455

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Dayvigo (NDC 62856-455). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eisai Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Structural Formula For Dayvigo Contains Lemborexant, An Orexin Receptor Antagonist. The Chemical Name Of Lemborexant Is (1r,2s)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-n-(5-fluoropyridin-2-yl) Cyclopropanecarboxamide. The Molecular Formula Is C22h20f2n4o2. The Molecular Weight Is 410.42. (Dayvigo 01)

FDA Label Image

Figure 1. Effects Of Hepatic And Renal Impairment On Lemborexant Pharmacokinetics (Dayvigo 02)

The text appears to be a graph or table displaying fold change and confidence intervals for hepatic and renal impairment. There is not enough information to provide a detailed description.*

FDA Label Image

Figure 2. Effects Of Co-administered Drugs On The Pharmacokinetics Of Lemborexant 10 mg (Dayvigo 03)

FDA Label Image

Figure 3. Effects Of Lemborexant 10 mg On The Pharmacokinetics Of Co-administered Drugs (Dayvigo 04)

This is a report on drug interaction based on changes and confidence intervals for CYP286 substrate. The report provides fold change values for various drugs including Supropon, Buaropon, VPR Subate, and Mazoiam, with respect to reference. The report also includes a graph showing changes in Auc (area under the curve) for Noratesione.*

FDA Label Image

Principal Display Panelndc 62856-405-30dayvigo(lemborexant) Tablets5 mg30 Tablets (Dayvigo 05)

FDA Label Image

Principal Display Panelndc 62856-405-90dayvigo(lemborexant) Tablets5 mg90 Tablets (Dayvigo 06)

This is a pharmaceutical label for a medication called "lemborexant". The label shows the dosage information and the prescription details for the medication. It also indicates the recommended temperature to store the medication and the precautions to take. The medication should be kept in a child-resistant container. The accompanying medication guide is also provided to the patient. No further information is available due to the limited text and lack of context.*

FDA Label Image

Principal Display Panelndc 62856-410-30dayvigo(lemborexant) Tablets10 mg30 Tablets (Dayvigo 07)

DAYVIGO is a medication that comes in tablet form and should be stored within the recommended temperature range, as detailed in the packaging. It should also be kept out of reach of children and dispensed in a chi-resistant container. The medication guide should be provided to the patient when dispensing this prescription-only medication. There is no information about the usual dosage, and the text includes a product code and the name of the manufacturer.*

FDA Label Image

Principal Display Panelndc 62856-410-90dayvigo(lemborexant) Tablets10 mg90 Tablets (Dayvigo 08)

DAYVIGO is a medication that comes in the form of tablets. The usual dosage should be checked on the package insert for prescribing information. The storage temperature is between 20°C to 25°C, with excursions allowed between 15°C to 30°C. It is important to keep DAYVIGO out of the reach of children and dispensed in a child-resistant container. The medication guide must be given to the patient along with the medication. The text includes a product code of NDC 62856-410-90 and indicates that the medication is for prescription-only. There is no information about the drug's usage or effects.*

FDA Label Image

Dayvigo 09

FDA Label Image

Dayvigo 0a

FDA Label Image

Dayvigo 0b

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.